Patient’s fertility desire should be taken into consideration in the surgical treatment algorithm of infiltrating endometriosis

To the Editor:

We read with great interest the manuscript by Fanfani et al., which reports their experience with laparoscopic treatment of bowel-infiltrating endometriosis (1). The authors analyzed their patients in regards to operative long-term complications, pain relief and recurrence rate, and suggest a surgical management algorithm. However, women with bowel endometriosis, besides having gastrointestinal symptoms and pain, frequently suffer from infertility.

The unresolved origin of uniparental diploid cell lines

To the Editor:

I should like to comment on the interesting report of Morales et al. (1) describing prenatally detected cases of androgenetic/biparental mosaicism.

Cross-over design trials in infertility: How much multiplicity is too much?

To the Editor:

We read with interest the article by Francavilla et al. published in the recent issue of the Journal (1). The authors set out to “analyze the effectiveness of intrauterine insemination with or without mild ovarian stimulation in male subfertility using a prospective cross-over design.”

Endometrial preparation for in vitro maturation treatment

To the Editor:

We read with great interest the paper published recently by Elizur et al. in the September 2009 edition of Fertility and Sterility (1). The authors compared retrospective data of two different protocols used to perform in vitro maturation treatment (IVM) based on physician preference: only micronized 17β-estradiol (6-12 mg/day) for endometrial preparation or human menopausal gonadotropins (HMG) 150 IU/day to induce both endometrial preparation and mild follicle stimulation.

Questions regarding the progesterone pharmacokinetic study.

To the Editor:

We disagree with the results of the trial by Blake et al. (1) with regard to the pharmacokinetics of Crinone and Endometrin.

Serum antimüllerian hormone (AMH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in women with polycystic ovary syndrome (PCOS).

To the Editor:

We have read with great interest the study by Singer et al. (1) and we would like to comment on the relationship between anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in polycystic ovary syndrome (PCOS).